Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

Eftozanermin alfa (eftoza), a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist, induces apoptosis in tumor cells by activation of death receptors 4/5. This phase 1 dose-escalation/dose-optimization study evaluated the safety, pharmacokinetics, phar...

Descripción completa

Detalles Bibliográficos
Autores principales: LoRusso, Patricia, Ratain, Mark J., Doi, Toshihiko, Rasco, Drew W., de Jonge, Maja J. A., Moreno, Victor, Carneiro, Benedito A., Devriese, Lot A., Petrich, Adam, Modi, Dimple, Morgan-Lappe, Susan, Nuthalapati, Silpa, Motwani, Monica, Dunbar, Martin, Glasgow, Jaimee, Medeiros, Bruno C., Calvo, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035501/
https://www.ncbi.nlm.nih.gov/pubmed/35467243
http://dx.doi.org/10.1007/s10637-022-01247-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035501/
https://www.ncbi.nlm.nih.gov/pubmed/35467243
http://dx.doi.org/10.1007/s10637-022-01247-1

Ejemplares similares